Cheat Sheet

Malignant Hyperthermia

Triggers and genes, early vs late signs, the MHAUS treatment order, dantrolene mixing, the first 24 hours in the ICU and look-alikes

Reviewed by Alex G, BSN, RN, CEN, CCRN, CMC, NREMT-P · Checked against current sources November 2026

Page 1 of the Malignant Hyperthermia PDF, a printed page in columns with sections on What you will do, Triggers and who is at risk, Early vs late signs, Treatment in order (MHAUS), Call for help when and Check your unit policy forEnlarge

One-page PDFLetter landscape, ready to print or keep with your notes

View PDFDownload

Malignant Hyperthermia: one-page PDF preview

Page 1 of the Malignant Hyperthermia PDF, a printed page in columns with sections on What you will do, Triggers and who is at risk, Early vs late signs, Treatment in order (MHAUS), Call for help when and Check your unit policy for

View PDFDownload

What you will do

Malignant hyperthermia (MH) is an inherited muscle disorder: volatile anesthetics or succinylcholine open a faulty calcium channel, and muscle burns energy out of control. Most crises start in the OR, but ICU nurses see it too: after succinylcholine for an intubation, with inhaled sedation, and as the patient sent up after a crisis.

Triggers and who is at risk

Early vs late signs

EMHG 2024 and MHAUS. Fever is often late; do not wait for it.
EarlyLate
EtCO₂ rising despite more ventilation (often first)Rapidly rising core temperature
Unexplained tachycardia, arrhythmias, unstable BPHyperkalemia, severe arrhythmias, cardiac arrest
Masseter spasm after succinylcholine; generalized rigidityCK very high; cola-colored urine (myoglobin)
Mixed respiratory and metabolic acidosis; sweating, mottled skinDIC, kidney injury, compartment syndrome

Treatment in order (MHAUS)

  1. Stop volatile agents and succinylcholine; continue with IV non-triggering drugs.
  2. Call for help and the MH cart (dantrolene); call the MHAUS hotline 1-800-644-9737.
  3. Hyperventilate with 100% oxygen at 10 L/min or more; charcoal filters on both circuit limbs if available.
  4. Dantrolene 2.5 mg/kg IV rapidly through a large-bore line. Repeat until EtCO₂ falls, rigidity eases and heart rate slows; more than 10 mg/kg may be needed.
  5. Cool if core temperature is over 39 °C or rising fast; stop cooling below 38 °C.
  6. Hyperkalemia: calcium, insulin with dextrose, bicarbonate. Arrhythmias: standard drugs, never calcium channel blockers.
  7. Bladder catheter; urine over 1 mL/kg/h (over 2 with myoglobinuria). Blood gas, K⁺, CK, urine myoglobin, coagulation.
  8. Transfer to PACU or ICU for at least 24 hours once stable.
Sterile water without preservative only: never saline or D5W. Use within 6 hours. Vesicant (pH about 9.5–10.3): watch the IV site.
RyanodexDantrium IV / Revonto
Vial250 mg20 mg (with 3 g mannitol)
Mix with5 mL sterile water60 mL sterile water
ResultOrange suspension; shake until uniformClear solution; shake until clear
80 kg first dose (200 mg)1 vial, 4 mL10 vials, 600 mL

Call for help when

Check your unit policy for

Where the MH cart lives and who restocks it, which dantrolene product your hospital stocks, how to get more from pharmacy or a nearby hospital, and whether volatile sedation is used in your ICU.

In depth

The one-page summary above is what the PDF prints. These sections go further.

What goes wrong in the muscle

In susceptible muscle, the ryanodine receptor (RYR1) releases too much calcium from the sarcoplasmic reticulum when exposed to a trigger. The muscle contracts, burns ATP and oxygen, and makes CO₂, lactate and heat. As cells fail, potassium, CK and myoglobin leak out. Dantrolene works inside the muscle by reducing this calcium release; it does not act at the neuromuscular junction.

Crises occur in about 1 in 10,000 to 1 in 250,000 anesthetics, but the genetic change may be present in as many as 1 in 400 people (Rosenberg 2015). Mortality has fallen from about 80% to under 5% with dantrolene, capnography and core temperature monitoring. More than 400 RYR1 variants are known; CACNA1S accounts for under 1%, and a STAC3 variant causes Native American myopathy with MH susceptibility.

Dantrolene in practice

The ICU phase: the first 24 hours and beyond

Hyperkalemia and acidosis doses (MHAUS, adult)

Children: insulin 0.1 unit/kg with 2 mL/kg of 25% dextrose.
ProblemTreatment
K⁺ over 5.9 mEq/L (5.9 mmol/L) or ECG changesCalcium chloride 10 mg/kg (max 2,000 mg) or calcium gluconate 10–50 mg/kg (max 3,000 mg)
Shift potassiumRegular insulin 10 units IV with 50 mL of 50% dextrose; glucose hourly
Metabolic acidosis (base deficit over 8)Sodium bicarbonate 1–2 mEq/kg IV
Refractory hyperkalemiaAlbuterol, dialysis; ECMO if in arrest

Look-alikes

EMHG 2024 also lists light anesthesia, anaphylaxis, pheochromocytoma, brain ischemia and recreational drugs such as ecstasy.
ConditionClueHow it differs from MH
Neuroleptic malignant syndromeAntipsychotic or stopped levodopaDevelops over days; lead-pipe rigidity, confusion
Serotonin syndromeSerotonergic drugsHours; clonus and hyperreflexia, diarrhea
Thyroid stormThyroid history, surgery or stressNo rigidity; high T4, low TSH
SepsisInfection sourceGradual; no rigidity; EtCO₂ rarely climbs fast
High EtCO₂ from the setupLaparoscopy, low fresh gas flowNo rigidity; resolves with more ventilation

After the crisis: the patient and family

Exam pearls

Practice in your browser4,850+ exam-style questions with rationales. No ads. Pro is coming in January 2027. Also on the App Store and Google Play.

Related cheat sheets

Calculators for this topic

Sources

  1. Malignant Hyperthermia Association of the United States (MHAUS). Managing a Crisis: emergency therapy for MH. Accessed November 2026. Link
  2. MHAUS. After a Crisis: Post-Acute Phase. Accessed November 2026. Link
  3. MHAUS Professional Advisory Council. Dantrolene administration after an MH event (2017 recommendation). Link
  4. Glahn KPE, Girard T, Hellblom A, et al; European Malignant Hyperthermia Group. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the EMHG. Br J Anaesth. 2025;134:221–223 (EMHG website version). Link
  5. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. Link
  6. Ryanodex (dantrolene sodium) for injectable suspension, prescribing information. Eagle Pharmaceuticals; DailyMed, November 2024. Link
  7. Revonto (dantrolene sodium) for injection, prescribing information. DailyMed, December 2025. Link
  8. Dantrium Intravenous (dantrolene sodium for injection), prescribing information. Par Health; DailyMed, April 2026. Link